<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03555526</url>
  </required_header>
  <id_info>
    <org_study_id>201706037MINC</org_study_id>
    <nct_id>NCT03555526</nct_id>
  </id_info>
  <brief_title>Genotypic Resistance Guided Therapy for Refractory H. Pylori Infection</brief_title>
  <official_title>Comparison of Genotypic Resistance Guided Versus Susceptibility Testing Guided Therapy for the Third-line Eradication of H. Pylori- a Multicenter Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Taiwan University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The inviestigators aimed to compare the efficacy of genotypic resistance guided versus
      susceptibility testing guided therapy in the third line treatment for refractory H. pylori
      infection.

      Hypothesis:The investigators hypothesized that genotypic resistance guided sequential therapy
      is non-inferior to empiric therapy in the third line treatment for refractory H. pylori
      infection.

      Methods: This multicenter, open label, parallel group, randomized trial will be conducted
      since 2017.07.20. Adult (≥20 years old) patients who failed from at least two eradication
      therapies for H. pylori infection will be enrolled. Genotypic and phenotypic resistances will
      be determined in patients who failed from at least two eradication therapies by
      polymerase-chain-reaction with direct sequencing and E-test and agar dilution test,
      respectively. Eligible patients will be randomized into either one of the treatment groups
      (A) genotypic resistance guided therapy; or (B) susceptibility testing guided therapy.

      Outcome Measurement The primary outcome is the eradication rate in the third line treatment
      (genotypic versus susceptibility testing guided therapy) according to intention-to-treat
      (ITT) analysis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The inviestigators aimed to compare the efficacy of genotypic resistance guided versus
      susceptibility testing guided therapy in the third line treatment for refractory H. pylori
      infection.

      Hypothesis:The investigators hypothesized that genotypic resistance guided sequential therapy
      is non-inferior to empiric therapy in the third line treatment for refractory H. pylori
      infection.

      Methods: This multicenter, open label, parallel group, randomized trial will be conducted
      since 2017.07.20. Adult (≥20 years old) patients who failed from at least two eradication
      therapies for H. pylori infection will be enrolled. Genotypic and phenotypic resistances will
      be determined in patients who failed from at least two eradication therapies by
      polymerase-chain-reaction with direct sequencing and E-test and agar dilution test,
      respectively. Eligible patients will be randomized into either one of the treatment groups
      (A) genotypic resistance guided therapy; or (B) susceptibility testing guided therapy.
      Eradication status will be determined by 13C-urea breath test at least 6 weeks after
      eradication therapy. The stool samples will be collected before, and 2 and 8 weeks and 1 year
      after eradication therapy to analyze the changes in the antibiotic resistance and microbiota
      of gut flora. The body weight, waist and hip circumference and serum lipid profile, sugar,
      and HbA1C levels will also be collected before and 2 weeks, 8 weeks and 1 year after
      eradication therapy.

      Outcome Measurement The primary outcome is the eradication rate in the third line treatment
      (genotypic versus susceptibility testing guided therapy) according to intention-to-treat
      (ITT) analysis.

      Secondary End Points: the eradication rate according per protocol analysis and the adverse
      effects

      Secondary End Point:

      (A) Eradication rate according to per protocol analysis (PP analysis) (B) Frequency of
      adverse effects (C) The changes in the gut microbiota, antibiotic resistance of the
      Enterobacteriae, metabolic parameters before and after H. pylori eradication (D) The long
      term eradication rate and reinfection rate
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 15, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Eradication rate by intention to treat analysis</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Eradication rate by per protocol analysis</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>frequency of adverse effects during eradication therapy</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes of fecal microbiota</measure>
    <time_frame>1 year</time_frame>
    <description>changes of fecal microbiota before and after erdication therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>reinfection rate</measure>
    <time_frame>1 year</time_frame>
    <description>reinfection rate 1 year after eradication therapy</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">320</enrollment>
  <condition>H Pylori Infection</condition>
  <arm_group>
    <arm_group_label>Genotypic resistance guided therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The regimen will be chosen according to the genotyping of 23S rRNA and gyrase A of H. pylori. In the absence of gyrase A mutation, esomeprazole (Nexium), amoxicillin (Amoxicillin), levofloxacin (Cravit), metronidazole (Flagyl) for 14 days will be given. In the presence of gyrase A mutation but in the absence of 23S rRNA mutation, esomeprazole (Nexium), amoxicillin (Amoxicillin), clarithromycin (Klaricid), metronidazole (Flagyl) for 14 days will be given. In the presence of both gyrase A and 23S rRNA mutation, bismuth quadruple therapy including esomeprazole (Nexium), bismuth (KCB), tetracycline, and metronidazole (Flagyl) for 10 days will be given.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phenotypic resistance guided therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The regimen will be chosen according to the susceptibility testing result. In the absence of levofloxacin resistance, esomeprazole (Nexium), amoxicillin (Amoxicillin), levofloxacin (Cravit), metronidazole (Flagyl) for 14 days will be given. In the presence of levofloxacin resistance but in the absence of clarithromycin resistance, esomeprazole (Nexium), amoxicillin (Amoxicillin), clarithromycin (Klaricid), metronidazole (Flagyl) for 14 days will be given. In the presence of both levofloxacin and clarithromycin resistance, bismuth quadruple therapy including esomeprazole (Nexium), bismuth (KCB), tetracycline, and metronidazole (Flagyl) for 10 days will be given.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Esomeprazole 40mg</intervention_name>
    <description>Nexium (esomeprazole), 40mg, bid, for 14 days</description>
    <arm_group_label>Genotypic resistance guided therapy</arm_group_label>
    <arm_group_label>Phenotypic resistance guided therapy</arm_group_label>
    <other_name>Nexium (Sequential)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amoxicillin</intervention_name>
    <description>amoxicillin, 1000mg, bid, for 7 days (day 1-day 7)</description>
    <arm_group_label>Genotypic resistance guided therapy</arm_group_label>
    <arm_group_label>Phenotypic resistance guided therapy</arm_group_label>
    <other_name>Amoxicillin (Sequential)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>metronidazole</intervention_name>
    <description>metronidazole, 500mg, bid, for 7 days (day 8-14)</description>
    <arm_group_label>Genotypic resistance guided therapy</arm_group_label>
    <arm_group_label>Phenotypic resistance guided therapy</arm_group_label>
    <other_name>Flagyl (sequential)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levofloxacin 500mg</intervention_name>
    <description>levofloxacin 250mg, bid, for 7 days (day 8-14)</description>
    <arm_group_label>Genotypic resistance guided therapy</arm_group_label>
    <arm_group_label>Phenotypic resistance guided therapy</arm_group_label>
    <other_name>Cravit (sequential)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clarithromycin ER</intervention_name>
    <description>clarithromycin 500mg, bid, for 7 days (day 8-14)</description>
    <arm_group_label>Genotypic resistance guided therapy</arm_group_label>
    <arm_group_label>Phenotypic resistance guided therapy</arm_group_label>
    <other_name>Klaricid ER 500 (sequential)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Esomeprazole 40mg</intervention_name>
    <description>Nexium (esomeprazole), 40mg, bid, for 10 days</description>
    <arm_group_label>Genotypic resistance guided therapy</arm_group_label>
    <arm_group_label>Phenotypic resistance guided therapy</arm_group_label>
    <other_name>Nexium (bismuth quadruple therapy)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dibismuth trioxide</intervention_name>
    <description>Dibismuth trioxide，KCB F.C. TABLETS，300mg，qid, for 10 days</description>
    <arm_group_label>Genotypic resistance guided therapy</arm_group_label>
    <arm_group_label>Phenotypic resistance guided therapy</arm_group_label>
    <other_name>KCB F.C.</other_name>
    <other_name>bismuth</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>metronidazole</intervention_name>
    <description>metronidazole, 500mg, tid, for 10 days (day 1-10)</description>
    <arm_group_label>Genotypic resistance guided therapy</arm_group_label>
    <arm_group_label>Phenotypic resistance guided therapy</arm_group_label>
    <other_name>Flagyl (bismuth quadruple)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tetracycline</intervention_name>
    <description>tetracycline 500mg, qid, for 10 days</description>
    <arm_group_label>Genotypic resistance guided therapy</arm_group_label>
    <arm_group_label>Phenotypic resistance guided therapy</arm_group_label>
    <other_name>tetracycline (bismuth quadruple therapy)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  H pylori infection failed after at least two eradication therapies

          -  aged 20 years or greater

          -  willingness to receive rescue therapy

        Exclusion Criteria:

          -  aged less than 20 years

          -  history of gastric resection surgery

          -  history of allergy to study drugs

          -  pregnancy or lactating women

          -  severe underlying illness, such as end stage renal disease, decompensated liver
             cirrhosis, or non-curative malignancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jyh-Ming Liou, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Taiwan University Hospital (recruiting)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yen-Nien Chen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Taiwan University Hospital Hsin-Chu Branch</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yu Jen Fang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Taiwan University Hospital, Yun-Lin Branch</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jyh-Ming Liou, MD, PhD</last_name>
    <phone>886972651883</phone>
    <email>jyhmingliou@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mei-Jyh Chen, MD</last_name>
    <phone>886223123456</phone>
    <phone_ext>63541</phone_ext>
    <email>migichen@ntuh.gov.tw</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Jyh-Ming Liou</name>
      <address>
        <city>Taipei, Taiwan</city>
        <state>Taiwan-</state>
        <zip>10002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jyh-Ming Liou</last_name>
      <email>jyhmingliou@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <study_first_submitted>December 14, 2017</study_first_submitted>
  <study_first_submitted_qc>June 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 13, 2018</study_first_posted>
  <last_update_submitted>June 12, 2018</last_update_submitted>
  <last_update_submitted_qc>June 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Metronidazole</mesh_term>
    <mesh_term>Clarithromycin</mesh_term>
    <mesh_term>Levofloxacin</mesh_term>
    <mesh_term>Ofloxacin</mesh_term>
    <mesh_term>Tetracycline</mesh_term>
    <mesh_term>Esomeprazole</mesh_term>
    <mesh_term>Bismuth</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

